Metro Boston Clinical Partners

Summary

Metro Boston Clinical Partners is a medical facility located in Brighton, Massachusetts. This center is recognized for care of Atopic Dermatitis, Plaque Psoriasis, Vitiligo, Medical Device Dermatitis, Psoriasis and other specialties. Metro Boston Clinical Partners is involved with conducting 28 clinical trials across 24 conditions. There are 1 research doctors associated with this hospital, such as Mark Amster.

Top PIs

Clinical Trials running at Metro Boston Clinical Partners

Psoriasis

Obesity

Plaque Psoriasis

Hidradenitis Suppurativa

Atopic Dermatitis

Acne

Childhood Obesity

Erythropoietic Protoporphyria

XLP

Prurigo Nodularis

Tirzepatide

for Psoriasis and Obesity

The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe plaque PsO and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.

Recruiting

3 awards

Phase 4

ESK-001

for Plaque Psoriasis

The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time. The scientific questions it aims to answer are: * How safe is taking ESK-001 long-term in people with moderate to severe plaque psoriasis? * Does taking ESK-001 long-term reduce the severity of people's plaque psoriasis? Patients will enter the long-term extension study following completion of one of the parent studies (ESK-001-016 or ESK-001-017) and will receive open-label ESK-001 twice daily for 24 weeks. After 24 weeks, the first 200 patients meeting at least PASI-75 clinical response will be randomly assigned to receive ESK-001 or placebo. At any point during this time, the patients losing the initial clinical response may return to the open-label ESK-001 treatment. Patients who complete Week 48 will return to open-label ESK-001 treatment and they will receive ESK-001 until the end of the study or discontinuation. All the remaining patients not meeting the entry criteria for the randomized withdrawal phase will continue to receive open-label ESK-001 for the remainder of the study. Patients taking part in the study must be men or women aged at least 18 years old and have completed a previous (parent) study of ESK-001 in moderate to severe plaque psoriasis. Patients must consent and agree to: * ensure drug daily compliance until end of study or discontinuation. * visit the clinic for checkups and assessments. * provide blood and urine samples.

Recruiting

1 award

Phase 3

1 criteria